Petros proprietary technology platform aligns with april 15, 2025 president trump executive order advancing rx-to-otc reclassification reforms

Company's ai and big data technology positioned to drive strong industry collaboration company also announces certain corporate actions new york, ny / access newswire / april 29, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today highlights president trump's april 15, 2025 executive order, titled, "lowering drug prices by once again putting americans first" (the "executive order"), as a demonstration that the company's recent strategic shift is well timed to the current regulatory climate, where petros believes it has already made significant advancements. petros' development of its big data and ai-driven software-as-a-medical device platform presents an important opportunity for the pharmaceutical industry to contribute to the lowering of drug prices while utilizing an emerging, yet proven, methodology that conforms with fda guidance to ensure a safe transition from rx to otc.
PTPI Ratings Summary
PTPI Quant Ranking